By McCann Health Managed Markets
In the United States, the prevalence of multiple morbidities is increasing and expected to become further dire in the near future. Multiple morbidities are two or more medical or psychiatric chronic conditions that last for a year or more and which exist in the same patient.
Such shift in the epidemiology of multiple morbidities stems from the rise in aging adults, increases in survivorship and life expectancy due to public health and medical interventions, and ongoing lifestyle risk factors that contribute to the diagnosis of chronic conditions. For pharmaceutical and biotechnology manufacturers, this urgent challenge presents a pivotal opportunity to address the care and cost complexities that emerge from patients who have multiple morbidities.
Common chronic conditions conducive to multiple morbidities include: heart disease, cancer, chronic lung disease, stroke, Alzheimer’s disease, diabetes, chronic kidney disease (key examples: cardio-oncology morbidities, cardio-metabolic conditions, psoriatic arthritis/cardiovascular disease, schizophrenia/diabetes, nash/diabetes)
Annual average out-of-pocket (OOP) costs and number of prescriptions increase substantially for patients with multiple morbidities.
Implications for payers, health systems and providers
Implications for patients
Manufacturers have an important and timely opportunity to demonstrate leadership by providing solutions across therapeutic areas within their portfolios that are commonly subject to multiple morbidities.
Turn to McCann Health Managed Markets to help you with developing your strategy and solutions in addressing the care and cost complexities of multiple morbidities, so that ultimately patients can better navigate their health.